A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2)

INTRODUCTION: Sepsis remains a major health problem with an increasing incidence, high morbidity and high mortality. Apart from treatment with antibiotics and organ support, no approved specific adjunct therapies currently exist. Adrenomedullin (ADM) is a vasoactive peptide. High plasma concentratio...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:BMJ Open
Huvudupphovsmän: Geven, Christopher, Blet, Alice, Kox, Matthijs, Hartmann, Oliver, Scigalla, Paul, Zimmermann, Jens, Marx, Gernot, Laterre, Pierre-François, Mebazaa, Alexandre, Pickkers, Peter
Materialtyp: Artigo
Språk:Inglês
Publicerad: BMJ Publishing Group 2019
Ämnen:
Intensive Care
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6377571/
https://ncbi.nlm.nih.gov/pubmed/30782906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2018-024475
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk